Differences in brain connections for people who carry a mutation known to cause Huntington’s disease are detectable decades before…
Articles by Marisa Horak, MS
Up to four years after a single dose of the experimental gene therapy ifezuntirgene inilparvovec (formerly AMT-130), people with…
In final 15-month study data, people with early-stage Huntington’s disease treated with SKY-0515, Skyhawk Therapeutics’ investigational oral therapy,…
uniQure has submitted an application to the U.S. Food and Drug Administration (FDA) seeking accelerated approval of AMT-130,…
Soma and Neurite Density Imaging (SANDI), an imaging technique that uses MRI scans to capture microstructural features of the brain,…
A novel gene-editing approach that’s designed to alter the huntingtin protein so it’s less prone to forming the toxic clumps…
A team led by scientists at a U.K. research organization has created a questionnaire to measure quality of life among…
A global clinical trial testing SKY-0515, Skyhawk Therapeutics’ daily oral therapy for Huntington’s disease, will soon start recruiting…
An early-stage clinical trial designed to test a novel stem cell therapy — one designed to replace lost or damaged…
SOM Biotech is preparing to launch a global late-stage clinical trial to evaluate whether SOM3355, its experimental oral therapy,…